Key points are not available for this paper at this time.
A prospective trial would be needed to determine whether younger patients with ICH without extensive bleeding at baseline can benefit from 80 mug/kg of rFVIIa given within 2.5 hours of symptom onset.
Mayer et al. (2009) studied this question.